Oncolytic vaccinia virus-mediated cancer cell lysis

The phrase "Cancer cell lysis via oncolytic vaccinia virus replication" does **not** refer to a single molecular target such as a receptor, enzyme, or protein. Instead, it describes a **therapeutic mechanism** wherein genetically engineered *oncolytic vaccinia viruses* selectively infect and replicate within cancer cells. This leads directly to **tumor cell lysis**, releasing new viral particles that can infect neighboring malignant cells. The process also triggers immunogenic cell death—releasing danger signals and tumor antigens—which stimulates both innate and adaptive anti-tumor immunity by recruiting cytotoxic T lymphocytes, natural killer cells, dendritic cells, and other effectors into the tumor microenvironment. These combined effects can remodel “cold” tumors into “hot” ones that are more susceptible to further immunotherapy interventions. Oncolytic vaccinia viruses may be further engineered with transgenes encoding cytokines or checkpoint inhibitors for enhanced efficacy. While promising as an innovative class of biological therapeutics against various cancers—including those resistant to standard treatments—this approach is not without challenges such as pre-existing antiviral immunity in patients (which may limit viral spread), potential off-target effects if selectivity is imperfect, inflammatory toxicities from excessive immune activation, and delivery barriers for systemic administration. In summary: this entry describes a **therapeutic strategy/process**, not an individual druggable molecule/receptor; thus it should not be considered a canonical therapeutic target but rather an approach employing live replicating agents with multifaceted mechanisms against cancer.[1][2][3]

Other names

Oncolytic vaccinia virusOVVoncolytic virotherapy (when referring to the approach)

Selective infection and replication within cancer cells leading to direct lysis[1][2][3] - Induction of immunogenic cell death and release of tumor antigens[1][2] - Activation of innate and adaptive anti-tumor immune responses (e.g., recruitment of cytotoxic T lymphocytes and NK cells)[1][2][3] - Modulation of the tumor microenvironment to enhance immune infiltration[3]